Carmen Hidalgo

598 total citations
18 papers, 301 citations indexed

About

Carmen Hidalgo is a scholar working on Infectious Diseases, Epidemiology and Immunology. According to data from OpenAlex, Carmen Hidalgo has authored 18 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 6 papers in Epidemiology and 5 papers in Immunology. Recurrent topics in Carmen Hidalgo's work include HIV/AIDS drug development and treatment (4 papers), HIV Research and Treatment (3 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Carmen Hidalgo is often cited by papers focused on HIV/AIDS drug development and treatment (4 papers), HIV Research and Treatment (3 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Carmen Hidalgo collaborates with scholars based in Spain, United States and Netherlands. Carmen Hidalgo's co-authors include José Luís Callejas-Rubio, Cándido Díaz‐Lagares, Francisco José García Hernández, Agustín Martínez-Berriotxoa, Luis Caminal‐Montero, Manuel Ramos‐Casals, Albert Selva-O’Callaghan, J. Oristrell, J Sánchez-Román and R. Pérez-Álvarez and has published in prestigious journals such as PLoS ONE, Lara D. Veeken and American Journal of Clinical Pathology.

In The Last Decade

Carmen Hidalgo

17 papers receiving 294 citations

Peers

Carmen Hidalgo

RHEUM

IMMUN

RNMI

EPIDE

PHYSI

Styliani I. Kokori Greece

Nick Pooley United States

Hisanori Nakayama Japan

Janette Kwok China

Kristján Erlendsson Iceland

Sara Sahl United States

Juan Sánchez‐Bursón Spain

Shirley R. R. Utiyama Brazil

Marlies Blom Netherlands

S S Badakere India

Styliani I. Kokori Greece

Carmen Hidalgo

143 ×1.1

RHEUM

107 ×0.9

IMMUN

24 ×0.5

RNMI

25 ×0.5

EPIDE

72 ×1.6

PHYSI

Citations per year, relative to Carmen Hidalgo Carmen Hidalgo (= 1×) peers Styliani I. Kokori

Countries citing papers authored by Carmen Hidalgo

Since Specialization

Citations

This map shows the geographic impact of Carmen Hidalgo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Hidalgo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Hidalgo more than expected).

Fields of papers citing papers by Carmen Hidalgo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen Hidalgo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Hidalgo. The network helps show where Carmen Hidalgo may publish in the future.

Co-authorship network of co-authors of Carmen Hidalgo

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen Hidalgo. A scholar is included among the top collaborators of Carmen Hidalgo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen Hidalgo. Carmen Hidalgo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

1.

Hidalgo, Carmen, et al.. (2025). Severe neonatal dengue with confirmed vertical transmission of DENV-3: A fatal case from Honduras. IDCases. 42. e02423–e02423.

2.

Delgado-Valverde, Mercedes, et al.. (2023). Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa. European Journal of Clinical Microbiology & Infectious Diseases. 43(3). 445–457. 6 indexed citations

3.

Palacios, Rosario, Cristina Gómez‐Ayerbe, José L. Casado, et al.. (2023). Efficacy and safety of dolutegravir/rilpivirine in real‐world clinical practice. GeSIDA study 1119. HIV Medicine. 24(8). 933–937. 3 indexed citations

4.

López‐Ruz, Miguel Ángel, M. Carmen Gonzálvo, Antonio Sampedro, et al.. (2018). Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients. PLoS ONE. 13(4). e0196257–e0196257. 4 indexed citations

5.

Hidalgo, Carmen, et al.. (2016). Characteristics and epidemiological changes for patients with urinary tract infection in the emergency department. Anales del Sistema Sanitario de Navarra. 39(1). 35–46. 4 indexed citations

6.

Hidalgo, Carmen, et al.. (2016). Characteristics and epidemiological changes for patients with urinary tract infection in the emergency department. Anales del Sistema Sanitario de Navarra. 39(1). 1 indexed citations

7.

Rodrigo, Teresa, Marta García‐Clemente, Ana Muñoz, et al.. (2015). Factors associated with unreported tuberculosis cases in Spanish hospitals. BMC Infectious Diseases. 15(1). 295–295. 14 indexed citations

8.

Pasquau, Juan, Carmen Hidalgo, Marisa Montes, et al.. (2012). A clinical trial to compare the quality of life of HIV+ patients who start monotherapy with LPV/r versus continuing triple therapy with a boosted PI. Journal of the International AIDS Society. 15(S4). 1–2. 1 indexed citations

9.

Díaz‐Lagares, Cándido, R. Pérez-Álvarez, Francisco José García Hernández, et al.. (2011). Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Research & Therapy. 13(4). R112–R112. 52 indexed citations

10.

Noureddine, Mariam, Javier de la Torre, Francisco José Martínez Martínez, et al.. (2011). Endocarditis sobre válvulas izquierdas por bacilos gran negativos: epidemiología y características clínicas. Enfermedades Infecciosas y Microbiología Clínica. 29(4). 276–281. 4 indexed citations

11.

Ramos‐Casals, Manuel, Francisco José García Hernández, José Luís Callejas-Rubio, et al.. (2010). Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.. PubMed. 28(4). 468–76. 102 indexed citations

12.

Palacios, Rosario, Carmen Hidalgo, Antonio Rivero, et al.. (2008). Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada®) in virologically suppressed HIV-infected patients on HAART. European Journal of Clinical Microbiology & Infectious Diseases. 28(4). 399–402. 7 indexed citations

13.

Orozco, Gisela, Peter Eerligh, Elena Sánchez, et al.. (2005). Analysis of a Functional BTNL2 Polymorphism in Type 1 Diabetes, Rheumatoid Arthritis, and Systemic Lupus Erythematosus. Human Immunology. 66(12). 1235–1241. 58 indexed citations

14.

Sánchez, Elena, Laura Paco, Miguel Ángel López‐Nevot, et al.. (2005). Interleukin 12 (IL12B), interleukin 12 receptor (IL12RB1) and interleukin 23 (IL23A) gene polymorphism in systemic lupus erythematosus. Lara D. Veeken. 44(9). 1136–1139. 32 indexed citations

15.

Hidalgo, Carmen, et al.. (2005). Two cases of catastrophic antiphospholipid syndrome. Lupus. 14(11). 907–909. 1 indexed citations

16.

Jiménez-Alonso, J, et al.. (2002). Hair dye treatment use and clinical course in patients with systemic lupus erythematosus and cutaneous lupus. Lupus. 11(7). 430–434. 5 indexed citations

17.

Hidalgo, Carmen, et al.. (2000). [Disseminated infection with Mycobacterium avium complex in immunocompetent patients].. PubMed. 18(7). 365–6. 2 indexed citations

18.

Hidalgo, Carmen & Adrian O. Vladutiu. (1987). Lupus Erythematosus Cells in Serum and Pleural Fluid of a Patient with Negative Fluorescent Antinuclear Antibody Test. American Journal of Clinical Pathology. 87(5). 660–662. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact